Clinical trials: Stage IV Pancreatic Cancer
- Condition Stage IV Pancreatic Cancer
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Pancreatic Neuroendocrine Tumors
Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China
To evaluate safety and efficacy of everolimus (Afinitor®) in Chinese adult patients with local advanced or metastatic, well differentiated progressive pancreatic neuroendocrine tumors.
- Trial name
- NCT02842749
- Testing
- everolimus
- Where
- 5 sites in China
- Volunteers
- 61 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Cancer
MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery
RATIONALE: Biological therapies, such as MDX-010, may stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00112580
- Testing
- ipilimumab
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Bristol-Myers Squibb
Breast Cancer Metastatic, Pancreatic Carcinoma Metastatic
Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors
Primary Objective: For Cohort A, Cohort B, and Cohort C Part 2: To assess the antitumor activity of tusamitamab ravtansine in metastatic breast cancer (mBC) and tusamitamab ravtansine monotherapy and in combination with…
- Trial name
- CARMEN-BT01 (NCT04659603)
- Testing
- tusamitamab ravtansine, Gemcitabine
- Where
- 29 sites in United States, Argentina and 8 more
- Volunteers
- 50 people
- Sponsor
- Sanofi
Metastatic Pancreatic Adenocarcinoma
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)
The purpose of this study is to determine whether CO-1.01 is safe and effective in the treatment of patients with metastatic pancreatic cancer and low hENT1 expression compared with gemcitabine.
- Trial name
- NCT01124786
- Testing
- CO-1.01, Gemcitabine
- Where
- 95 sites in United States, Argentina and 13 more
- Volunteers
- 367 people
- Sponsor
- Clovis Oncology, Inc.
Advanced Cancer, Pancreatic Cancer Metastatic
Safety Study of Whole Body Hyperthermia for Advanced Cancer
Millions of patients die of cancer every year. There are several methods to treat cancer, including surgery, chemotherapy, radiotherapy and immunotherapy. Recently, hyperthermia therapy started playing a role in cancer therapy.
- Trial name
- MATTERS (NCT04467593)
- Testing
- Whole body hyperthermia, Standard of Care (SOC) chemotherapy according to the NCCN guidelines.
- Where
- Belgium
- Volunteers
- 16 people
- Sponsor
- ElmediX
Pancreatic Neoplasms
A Randomized Study of Amplimexon (Imexon) With Gemcitabine in Pancreatic Cancer
The purpose of this study is to determine if imexon in combination with gemcitabine could improve overall survival as compared to gemcitabine alone in subjects with pancreatic cancer that has spread to other organs such as the…
- Trial name
- NCT00637247
- Testing
- imexon in combination with gemcitabine
- Where
- 48 sites in United States
- Volunteers
- 142 people
- Sponsor
- AmpliMed Corporation
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Pancreatic Cancer
Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00625586
- Testing
- RAV12, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- MacroGenics
Metastatic Pancreatic Cancer
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer
This study is designed to compare the treatment effect of PEGPH20 combined with nab-paclitaxel (NAB) and gemcitabine (GEM) [PAG] to NAB and GEM [AG] in participants with Stage IV previously untreated pancreatic ductal…
- Trial name
- NCT01839487
- Testing
- PEGPH20, Nab-paclitaxel, Gemcitabine
- Where
- 51 sites in United States
- Volunteers
- 279 people
- Sponsor
- Halozyme Therapeutics
Stage IV Pancreatic Cancer
Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer
Phase 1B: Open label (all patients receive PEGPH20+gemcitabine), dose escalation, safety and tolerability study to determine the safe dose of PEGPH20 to use in combination with gemcitabine in Stage IV previously untreated…
- Trial name
- NCT01453153
- Testing
- Gemcitabine, PEGPH20
- Where
- 12 sites in United States, Russia
- Volunteers
- 28 people
- Sponsor
- Halozyme Therapeutics
Pancreatic Ductal Carcinoma
A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
The purpose of this study is to compare the efficacy and safety of PEGylated Recombinant Human Hyaluronidase (PEGPH20) combined with nab-paclitaxel plus gemcitabine (PAG treatment), compared with placebo combined with…
- Trial name
- NCT02715804
- Testing
- Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20), nab-Paclitaxel, Gemcitabine
- Where
- 217 sites in United States, Australia and 20 more
- Volunteers
- 492 people
- Sponsor
- Halozyme Therapeutics
Cachexia
Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas
A safety \& efficacy clinical study of the investigational medicinal product BYM338 for the treatment of unintentional weight loss in patients with cancer of the lung or the pancreas
- Trial name
- NCT01433263
- Testing
- BYM338 active drug
- Where
- 10 sites in United States, Lithuania and 3 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Gastric Adenocarcinoma, Esophageal Cancer
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
The primary objective in Phase I is to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial…
- Conditions
- Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT01631552
- Testing
- Sacituzumab Govitecan-hziy (SG)
- Where
- 12 sites in United States
- Volunteers
- 515 people
- Sponsor
- Gilead Sciences
Stage IV Pancreatic Cancer
A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer
The study consists of a Phase1b lead-in portion to determine the maximum tolerated dose (MTD) of OMP-59R5 in combination with nab-paclitaxel and gemcitabine followed by a Phase 2, multicenter, randomized, placebo-controlled…
- Trial name
- ALPINE (NCT01647828)
- Testing
- OMP-59R5, Gemcitabine, Nab-Paclitaxel
- Where
- 26 sites in United States
- Volunteers
- 217 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.